Publications by authors named "S Thirupathi Kumara Raja"
Aneurysmal Subarachnoid Hemorrhage (aSAH), resulting from ruptured aneurysms, is a major contributor to stroke-related mortality and morbidity. Despite advances in healthcare, aSAH remains severe and often leads to complications such as cerebral vasospasm (CV), cerebral infarction, and delayed ischemic neurological deficits (DIND). Clazosentan, an endothelin receptor antagonist, has demonstrated potential in alleviating vasospasm and its associated outcomes, although evidence of its efficacy remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- Dapagliflozin is a promising treatment for Acute Heart Failure (AHF), showing benefits in reducing cardiovascular mortality and hospital readmissions compared to traditional therapies.
- A systematic review of five randomized controlled trials indicated that dapagliflozin significantly lowered in-hospital cardiovascular mortality rates and 30-day hospital readmissions without impacting hospital stay length or hypotension incidents.
- The research followed established protocols for data extraction and quality assessment, demonstrating a notable weight change in patients receiving dapagliflozin, reinforcing its efficacy as a treatment option in AHF.
This study investigates the production of graphene-enhanced polyethylene terephthalate glycol (G-PETG) components using fused deposition modeling (FDM) and evaluates their mechanical properties, contributing to the advancement of additive manufacturing. Trials demonstrated notable improvements in mechanical performance, with optimal printing parameters identified using the Spice Logic Analytical Hierarchy Process (AHP). The effectiveness of this methodology is further compared with the Fuzzy Analytic Hierarchy Process (FAHP) combined with the Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS).
View Article and Find Full Text PDFObjective: Based on current practice guidelines, we hypothesized that most patients with esophageal cancer, particularly those with locally advanced cancer, would benefit from adjuvant therapy after esophagectomy esophagectomy alone. We sought to obtain a granular estimate of patient-level risk-adjusted survival for each therapeutic option by cancer histopathology and stage.
Background: Although esophagectomy alone is now an uncommon therapy for treating locally advanced esophageal cancer, the value of adjuvant therapy after esophagectomy is unknown.